New pill combo aims to wipe out breast tumors before surgery
NCT ID NCT04290793
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the targeted drug pyrotinib to standard chemotherapy and trastuzumab can completely eliminate HER2-positive breast tumors before surgery. About 113 women with early-stage HER2+ breast cancer will receive the combination, then have surgery to check for any remaining cancer. The goal is to see if this approach improves the chance of a complete response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pyrotinib (a targeted cancer pill) combined with chemotherapy drugs (epirubicin, cyclophosphamide, docetaxel) and trastuzumab (a targeted antibody)
What this could lead to
If successful, this combination could become a new standard neoadjuvant treatment to shrink or eliminate HER2-positive breast tumors before surgery, potentially reducing recurrence risk.
What could go wrong
This is a single-arm phase 2/3 trial with no comparison group, so results are preliminary. Side effects from the drug combination may be significant, and the regimen may not outperform existing therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China